Effect of epidermal growth factor receptor mutations on the response to epidermal growth factor receptor tyrosine kinase inhibitors: Target-based populations for target-based drugs

Clinical Lung Cancer

Volumn 6, Issue SUPPL. 1, 2004, Pages

  Calvo, Emiliano ^a   Rowinsky, Eric K ^a  

^a CTRC Institute for Drug Development   (United States)

Author keywords

Erlotinib; Gefitinib; Interstitial lung disease

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE; IMATINIB; INTERLEUKIN 2; MONOCLONAL ANTIBODY; PACLITAXEL; PLACEBO; STEM CELL FACTOR; TRASTUZUMAB;

AMINO ACID SUBSTITUTION; ARTICLE; CANCER GENETICS; CANCER GROWTH; CLINICAL TRIAL; DRUG EFFECT; DRUG ERUPTION; DRUG MECHANISM; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TARGETING; GASTROINTESTINAL STROMAL TUMOR; HUMAN; INTERSTITIAL LUNG DISEASE; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MUTATIONAL ANALYSIS; NONHUMAN; PATIENT SELECTION; POPULATION RESEARCH; PROBABILITY; PROSPECTIVE STUDY; SEQUENCE ANALYSIS; SKIN TOXICITY; SOMATIC MUTATION; VALIDATION PROCESS;

EID: 12744253732     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2004.s.013     Document Type: Article

References (57)

1. Andratschke NH, Dittmann KH, Mason KA, et al. Epidermal growth factor receptor as a target to improve treatment of lung cancer. Clin Lung Cancer 2004; 5:340-352.
2. Shepherd FA, Pereira J, Ciuleanu TE, et al. A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial. Late-breaking abstract from the 2004 ASCO Annual Meeting. J Clin Oncol 2004; 22(suppl):7022.
3. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290:2149-2158.
4. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 21:2237-2246.
5. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1. J Clin Oncol 2004; 22:777-784.
6. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J Clin Oncol 2004; 22:785-794.
7. Herbst RS, Prager D, Hermann R, et al. TRIBUTE - A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2004; 23:617 (Abstract #7011).
8. Gatzemeier U, Pluzanska A, Szczesna A, et al. Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2004; 23:617 (Abstract #7010).
9. Perez-Soler R. The role of erlotinib (Tarceva, OSI 774) in the treatment of non-small cell lung cancer. Clin Cancer Res 2004; 10:42(suppl):38S-4240S.
10. Hainsworth JD, Mainwaring MG, Thomas M, et al. Gefitinib in the treatment of advanced, refractory non-small-cell lung cancer: results in 124 patients. Clin Lung Cancer 2003; 4:347-355.
11. Sandler A, Blumenschein R, Henderson T, et al. Phase I/II trial evaluating the anti-VEGF MAb bevacizumab in combination with erlotinib, a HER1/EGFR-TK inhibitor, for patients with recurrent non-small cell lung cancer. Proc Am Soc Clin Oncol 2004; 23:127 (Abstract #2000).
12. Nishiwaki Y, Yano S, Tamura T, et al. [Subset analysis of data in the Japanese patients with NSCLC from IDEAL 1 study on gefitinib]. Gan To Kagaku Ryoho 2004; 31:567-573.
13. Miller VA, Herbst RS, Prager D, et al. Long survival of never smoking non-small cell lung cancer (NSCLC) patients (pts) treated with erlotinib HCl (OSI-774) and chemotherapy: sub-group analysis of TRIBUTE. Proc Am Soc Clin Oncol 2004; 23:628 (Abstract #7061).
14. Miller VA, Kris MG, Shah N, et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 2004; 22:1103-1109.
15. Miller V, Patel J, Shah N, et al. The epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) shows promising activity in patients with bronchioloalveolar cell carcinoma (BAC): preliminary results of a phase II trial. Proc Am Soc Clin Oncol 2003; 22:619 (Abstract #2491).
16. Clark GM, Perez-Soler R, Siu L, et al. Rash severity is predictive of increased survival with erlotinib HCl. Proc Am Soc Clin Oncol 2003; 22:196 (Abstract #786).
17. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-2139.
18. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304:1497-1500.
19. Janne PA. EGFR Mutations Predict Response to Gefitinib - Now What? [Education Program]. Presented at the 40th Annual Meeting of the American Society of Clinical Oncology; June 5-8, 2004; New Orleans, LA.
20. Pao W, Miller V, Zakowski M, et al. ECT receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004; 101:13306-13311.
21. Reiter JL, Threadgill DW, Eley GD, et al. Comparative genomic sequence analysis and isolation of human and mouse alternative EGFR transcripts encoding truncated receptor isoforms. Genomics 2001; 71:1-20.
22. Downward J, Yarden Y, Mayes E, et al. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature 1984; 307:521-527.
23. Frederick L, Wang XY, Eley G, et al. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 2000; 60:1383-1387.
24. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2:127-137.
25. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003; 21:3798-3807.
26. Rusch V, Klimstra D, Venkatraman E, et al. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res 1997; 3:515-522.
27. Mukohara T, Kudoh S, Matsuura K, et al. Activated Akt expression has significant correlation with EGFR and TGF-alpha expressions in stage I NSCLC. Anticancer Res 2004; 24:11-17.
28. Okamoto I, Kenyon LC, Emlet DR, et al. Expression of constitutively activated EGFRvIII in non-small cell lung cancer. Cancer Sci 2003; 94:50-56.
29. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21:4342-4349.
30. Minna JD, Gazdar AF, Sprang SR, et al. Cancer. A bull's eye for targeted lung cancer therapy. Science 2004; 304:1458-1461.
31. Brabender J, Danenberg KD, Metzger R, et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res 2001; 7:1850-1855.
32. Meert AP, Martin B, Delmotte P, et al. The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis. Eur Respir J 2002; 20:975-981.
33. Arteaga CL. EGFR Mutations Predict Response to Gefitinib - Now What? [Education Program]. Presented at the 40th Annual Meeting of the American Society of Clinical Ontology; June 5-8, 2004; New Orleans, LA.
34. Chakravarti A, Loeffler JS, Dyson NJ. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 2002; 62:200-207.
35. Bianco R, Shin I, Ritter CA, et al. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 2003; 22:2812-2822.
36. Christensen JG, Schreck RE, Chan E, et al. High levels of HER-2 expression alter the ability of epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitors to inhibit EGFR phosphorylation in vivo. Clin Cancer Res 2001; 7:4230-4238.
37. Viloria-Petit A, Crombet T, Jothy S, et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res 2001; 61:5090-5101.
38. Heimberger AB, Learn CA, Archer GE, et al. Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res 2002; 8:3496-3502.
39. Inoue A, Saijo Y, Maemondo M, et al. Severe acute interstitial pneumonia and gefitinib. Lancet 2003; 361:137-139.
40. Ciardiello F, De Vita F, Orditura M, et al. The role of EGFR inhibitors in non small cell lung cancer. Curr Opin Oncol 2004; 16:130-135.
41. Soria JC, Le Chevalier T. Interstitial lung disease in NSCLC. Sigma 2003; 4:2-3.
42. Baughman RP, Lower EE, Miller MA, et al. Overexpression of transforming growth factor-alpha and epidermal growth factor-receptor in idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16:57-61.
43. Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001; 134:136-151.
44. Takano T, Ohe Y, Kusumoto M, et al. Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib. Lung Cancer 2004; 45:93-104.
45. Suzuki H, Aoshiba K, Yokohori N, et al. Epidermal growth factor receptor tyrosine kinase inhibition augments a routine model of pulmonary fibrosis. Cancer Res 2003; 63:5054-5059.
46. Cohen EE, Rosen F, Stadler WM, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003; 21: 1980-1987.
47. Saltz L, Kies M, Abbruzzese JL, et al. The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. Proc Am Soc Clin Oncol 2003; 22:204 (Abstract #817).
48. Soulieres D, Senzer NN, Vokes EE, et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004; 22:77-85.
49. Hidalgo M, Siu LL, Nemunaitis J, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001; 19:3267-3279.
50. Baselga J, Rischin D, Ranson M, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002; 20:4292-4302.
51. Herbst RS, Maddox AM, Rothenberg ML, et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol 2002; 20:3815-3825.
52. Matar P, Rojo F, Guzman M, et al. Combined anti-epidermal growth factor receptor (EGFR) treatment with a tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) and a monoclonal antiboday (IMC-C225): evidence of synergy. Proc Am Assoc Cancer Res 2003; 44:917 (Abstract #4007).
53. Huang S, Armstrong EA, Benavente S, et al. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res 2004; 64:5355-5362.
54. Arteaga CL. ErbB-targeted therapeutic approaches in human cancer. Exp Cell Res 2003; 284:122-130.
55. Yamazaki H, Fukui Y, Ueyama Y, et al. Amplification of the structurally and functionally altered epidermal growth factor receptor gene (c-erbB) in human brain tumors. Mol Cell Biol 1988; 8:1816-1820.
56. Rich JN, Reardon DA, Peery T, et al. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 2004; 22:133-142.
57. Rowinsky EK. Curtailing the high rate of late-stage attrition of investigational therapeutic agents against unprecedented targets in patients with lung and other malignancies. Clin Cancer Res 2004; 10(suppl):4220S-4226S.